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Objectives:	   To	   highlight	   the	   occurrence	   of	   Hashimoto’s	   encephalopathy	   –	   a	   steroid-­‐responsive	   encephalopathy	  
associated	  with	  elevated	  antithyroid	  antibodies.	   	  
	  
Material	  and	  methods:	  We	  describe	  a	  clinically	  and	  biochemically	  euthyroid	  patient	  with	  an	  encephalopathy	  presenting	  
with	  headache,	  mild	  confusion	  and	  personality	  changes	  for	  6	  weeks	  and	  tonic–clonic	  seizures	  upon	  admission	   	  
	  
Results:	  There	  was	  no	  obvious	   infective	  or	  metabolic	  cause.	  The	  patient	  had	  a	  high	  titre	  of	  antithyroid	  antibodies	  and	  
responded	  to	  steroid	  therapy.	  
	  
Conclusion:	   This	   uncommon	   disease	   needs	   to	   be	   considered	   in	   patients	   presenting	  with	   neurological	   symptoms	   that	  
remain	   unexplained	   after	   routine	   standard	   investigations,	   even	   when	   the	   patient	   is	   euthyroid.	   Early	   diagnosis	   is	  
important,	  as	  this	  is	  a	  treatable	  condition.	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Introduction	  
Hashimoto’s	  encephalopathy	  (HE)	   is	  a	  neurologic	  syndrome	  associated	  with	  Hashimoto’s	  thyroiditis.	   Initially	  described	  
in	  1966	  [1],	  it	  is	  thought	  to	  be	  autoimmune	  because	  of	  its	  association	  with	  other	  immunologic	  disorders,	  inflammatory	  
findings	   in	  cerebrospinal	   fluid	  (CSF)	  and	  response	  to	  treatment	  with	  steroids	  [1]	  or	  an	  autoimmune	  cerebral	  vasculitis	  
resulting	  from	  either	  endothelial	  inflammation	  or	  immune	  complex	  deposition	  [1].	   	  
	  
Case	  report	   	  
This	  55-­‐year-­‐old	  female	  patient	  was	  a	  smoker	  and	  a	  teetotaller	  and	  was	  not	  known	  to	  have	  diabetes	  or	  hypertension.	  
The	   patient	   had	   a	   history	   of	   hypothyroidism;	   she	   was	   taking	   125	   μg	   levothyroxine	   daily	   and	   was	   clinically	   and	  
biochemically	   euthyroid.	   She	   presented	   with	   a	   gradually	   worsening	   constant	   dull	   frontal	   headache,	   photophobia,	  
confusion	  and	  personality	  changes	  over	  the	  previous	  6	  weeks.	  She	  was	  treated	  for	  migraine	  by	  her	  family	  doctor	  with	  no	  
improvement.	   She	  was	   disorientated	   and	  developed	   generalized	   tonic–clonic	   seizures.	   She	  was	   started	  on	  phenytoin	  
and	  phenobarbitone.	  Her	  seizures	  resolved,	  but	  the	  other	  symptoms	  persisted.	  There	  was	  no	  history	  of	  fever,	  vomiting,	  
loss	  of	  consciousness,	  drug	  intake,	  exposure	  to	  toxins	  or	  recent	  travel.	  She	  did	  not	  have	  any	  previous	  neurological	  deficit.	  
She	  had	  normal	  bowel	  and	  bladder	  habits.	  There	  was	  no	  similar	  illness	  in	  family	  members.	  
She	  was	  confused	  and	  afebrile,	  with	  no	  skin	  rash,	  neck	  stiffness	  or	  Kernig’s	  sign.	  She	  had	  word-­‐finding	  difficulty,	  ataxic	  
gait	  and	  right	  visual	  field	  visual	  loss.	  Neurological	  examination	  and	  systemic	  examination	  were	  otherwise	  normal.	   	  
ELISA	  for	  HIV	  was	  nonreactive	  as	  was	  hepatitis	  screening.	  Vasculitis	  screening	  and	  syphilis	  immunoassay	  were	  negative.	  
CSF	  was	  negative	  for	  viral	  studies	  and	  showed	  no	  evidence	  of	  xanthochromia,	  bacterial,	  tuberculous	  or	  fungal	  infection.	  
The	   computed	   tomography	   scan	   showed	   narrow	   triangular	   opacities	   in	   the	   left	   occipital	   and	   right	   frontal	   lobes,	   but	  
magnetic	  resonance	  imaging	  (MRI)	  scan	  of	  the	  brain	  was	  normal.	  Electroencephalography	  studies	  showed	  intermittent	  
high-­‐amplitude	  slow	  wave	  activity.	  
The	  serum	  anti-­‐TPO	  was	  high:	  >1300	  U/ml	  (biological	  reference	  interval	  of	  >60	  U/ml	  considered	  positive).	  However,	  the	  
serum	  FT4	  and	  TSH	  were	  normal.	   	  
A	   diagnosis	   of	   HE	  was	  made	   and	   the	   patient	  was	   started	   on	   intravenous	   dexamethasone.	   There	  was	   a	   rapid	   clinical	  
response.	  She	  was	   switched	   to	  oral	  prednisone,	   starting	  at	  1	  mg/kg	  daily,	  with	  a	   slow	   taper.	  At	  her	   routine	  check-­‐up	  
after	  3	  weeks,	  she	  had	  experienced	  significant	  resolution	  of	  symptoms.	  
	  
Discussion	  
A	  systematic	  review	  of	  HE	  [1]	  reported	  85	  cases	  and	  a	  hospital-­‐based	  study	  estimated	  a	  frequency	  of	  2.1/100,000	  [2].	  
Two	  major	  patterns	  of	   presentation	   are	  described:	   25%	  of	   patients	   follow	  a	   stroke-­‐like	  pattern	  of	  multiple	   recurrent	  
episodes	  of	  focal	  neurologic	  deficits	  with	  a	  variable	  degree	  of	  cognitive	  dysfunction	  and	  consciousness	  impairment	  [1];	  
the	  remaining	  75%	  present	  with	  a	  diffuse	  progressive	  pattern	  of	  slow	  cognitive	  decline	  with	  dementia,	  confusion	  and	  
hallucinations	  [1,	  2].	  These	  two	  clinical	  patterns	  may	  overlap	  over	  the	  course	  of	  the	  disease.	  Two-­‐thirds	  of	  patients	  may	  
experience	  focal	  or	  generalized	  tonic–clonic	  seizures	  and	  12%	  may	  present	  with	  status	  epilepticus.	  Myoclonus	  or	  tremor	  
is	  seen	  in	  up	  to	  38%	  of	  patients,	  hyperreflexia	  and	  other	  pyramidal	  tract	  signs	  are	  seen	  in	  85%	  of	  patients	  and	  psychosis,	  
visual	  hallucinations	  and	  paranoid	  delusions	  have	  been	  reported	  in	  25%–36%	  of	  patients	  [1].	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Elevated	  serum	  levels	  of	  antithyroid	  antibodies	  remains	  an	  essential	  characteristic	  of	  HE	  [1].	  The	  mechanism	  of	  HE	  does	  
not	   appear	   to	   be	   related	   to	   the	   clinical	   functional	   thyroid	   status.	   In	   reported	   series,	   23%–35%	   of	   patients	   were	  
subclinically	  hypothyroid,	  17%–20%	  hypothyroid,	  7%	  hyperthyroid	  and	  18%–45%	  euthyroid	  [1].	  
The	  pathogenic	  role	  of	  thyroid	  antibodies	  remains	  unknown.	  There	  is	  no	  evidence	  that	  any	  antithyroid	  antibody	  reacts	  
with	   brain	   tissue	   or	   affects	   nerve	   function,	   and	   there	   is	   no	   clear	   correlation	   between	   the	   severity	   of	   the	   neurologic	  
symptoms	  and	  the	  concentration	  of	  these	  antibodies	  [1,	  2].	  The	  resolution	  of	  symptoms	  with	  plasmapheresis	  supports	  
an	  autoimmune	  aetiology	  [3].	  
In	  one	  case	  series,	  9	  of	  12	  patients	  with	  encephalopathy	  and	  elevated	  serum	  antithyroid	  antibodies	  had	  elevated	  CSF	  
autoantibody	  titres	  [2].	  A	  systematic	  review	  found	  that	  13%	  of	  published	  cases	  of	  HE	  reported	  antithyroid	  antibodies	  in	  
the	  CSF.	  However,	  the	  titres	  of	  antithyroid	  antibodies	  in	  the	  CSF	  do	  not	  correlate	  with	  the	  clinical	  stage	  of	  the	  disease,	  
and	  the	  sensitivity	  and	  specificity	  of	  this	  finding	  remain	  unclear	  [2].	  An	  autoantibody	  against	  the	  amino	  terminal	  end	  of	  
the	   enzyme	   α-­‐enolase,	   an	   antigen	   of	   the	   thyroid	   and	   the	   brain,	   has	   been	   identified	   as	   a	   potential	   biomarker	   of	  
Hashimoto's	  encephalopathy	  [4].	  Serum	  autoantibody	  reactivity	  occurred	  in	  5	  of	  6	  patients	  with	  HE	  compared	  with	  2	  of	  
17	  patients	  with	  Hashimoto's	  thyroiditis	  but	  no	  encephalopathy	  and	  in	  none	  of	  25	  healthy	  control	  subjects	  [4].	   	  
CSF	  analysis	   results	  were	  normal	   in	  our	  patient	  but	  a	   lymphocytic	  pleocytosis	   is	   reported	   in	  14%	  of	  patients	  and	  may	  
contain	  more	  than	  100	  cells/mm3	  in	  4%.	  An	  elevated	  protein	  concentration	  occurs	  in	  78%	  of	  patients	  [1].	   	  
Non-­‐specific	  EEG	  abnormalities	  are	  seen	  in	  90%–98%	  patients,	  which	  is	  usually	  a	  non-­‐specific	  slow	  background	  activity.	  
The	   same	   pattern	  was	   observed	   in	   our	   patient.	   Focal	   spikes	   or	   sharp	  waves	   and	   transient	   epileptic	   activity	   are	   less	  
common	   [5].	   In	   a	   review	   of	   82	   patients	  with	   HE,	   brain	   computed	   tomography	   or	  MRI	   showed	   abnormalities	   in	   49%	  
patients,	   such	   as	   cerebral	   atrophy,	   focal	   cortical	   abnormality,	   diffuse	   subcortical	   abnormality	   and	   non-­‐specific	  
subcortical	  focal	  white	  matter	  abnormality.	  
The	   long-­‐term	  prognosis	   is	   variable,	  with	   some	   patients	   having	   a	   progressive	   or	   a	   relapsing	   course	   [1].	   A	   systematic	  
review	  of	  85	  published	  cases	  of	  HE	  found	  clinical	  response	   in	  98%	  patients	  treated	  with	  glucocorticoids,	  92%	  patients	  
treated	  with	  glucocorticoids	  and	  levothyroxine	  and	  67%	  of	  patients	  treated	  with	  levothyroxine	  only	  [1].	   	  
The	  differential	  diagnosis	  of	  Hashimoto's	  encephalopathy	  must	  consider	  any	  condition	  associated	  with	  delirium,	  rapidly	  
progressive	  dementia,	  seizures	  or	  focal	  neurologic	  deficits	  and	  may	  include	  stroke,	  transient	  ischaemic	  attack,	  cerebral	  
vasculitis,	   carcinomatous	   meningitis,	   toxic	   metabolic	   encephalopathies,	   paraneoplastic	   syndromes,	   Creutzfeldt-­‐Jakob	  
disease,	  degenerative	  dementia	  and	  psychiatric	  diseases	  [1].	  However,	  the	  possibility	  of	  another	  coexisting	  autoimmune	  
steroid-­‐responsive	  disease	  needs	  to	  be	  excluded,	  and	  patients	  must	  be	  kept	  under	  surveillance.	  
	  
Conclusion	  
HE	   should	   be	   considered	   in	   all	   patients	  with	   encephalopathy	   of	   undetermined	   aetiology.	  Measuring	   thyroid	   function	  
alone	  may	   not	   capture	   patients	   such	   as	   ours	   and	   the	   18%–45%	   of	   euthyroid	   patients	   reported	   in	   the	   literature	   [1].	  
Measurement	  of	  thyroid	  antibodies	  should	  be	  considered	  in	  patients	  with	  encephalopathy	  of	  undetermined	  origin,	  even	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Learning	  Points	  
	  
• Hashimoto’s	  encephalopathy	  is	  a	  neurologic	  syndrome	  associated	  with	  Hashimoto's	  thyroiditis	  and	  is	  thought	  to	  
be	   autoimmune	   because	   of	   its	   association	   with	   other	   immunologic	   disorders,	   inflammatory	   findings	   in	   the	  
cerebrospinal	  fluid	  and	  response	  to	  treatment	  with	  steroids	  or	  an	  autoimmune	  cerebral	  vasculitis	  resulting	  from	  
either	  endothelial	  inflammation	  or	  immune	  complex	  deposition.	  
• The	  variable	  and	  non-­‐specific	  clinical	  presentations	  often	  lead	  to	  a	  delay	  in	  diagnosis	  and	  initiation	  of	  treatment	  
of	  Hashimoto's	  encephalopathy.	   	  
• Hashimoto’s	   encephalopathy	   should	   be	   considered	   in	   all	   patients	   with	   encephalopathy	   of	   undetermined	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